Octreotide acetate is indicated to reduce blood levels of growth hormone in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. 
Octreotide acetate is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. 
Octreotide acetate is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors.
Active ingredient Pharmaceutical form Package Therapeutic target
  • Octreotide LAΙ
  • Long-Acting Injectable
  • 10mg/Vial 
  • 20mg/Vial 
  • 30mg/Vial
  • Hormone Replacement Therapy-Treatment of Diarrhea

Other products in "International"